Tumor infiltrating lymphocytes in ovarian cancer

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 9, 2015, Pages 3635-3638

  Gasparri, Maria Luisa ^a   Attar, Rukset ^b   Palaia, Innocenza ^a   Perniola, Giorgia ^a   Marchetti, Claudia ^a   Di Donato, Violante ^a   Farooqi, Ammad Ahmad ^c   Papadia, Andrea ^d   Panici, Pierluigi Benedetti ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b YEDITEPE UNIVERSITY   (Turkey)

^c RASHID LATIF MEDICAL COLLEGE   (Pakistan)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

Apoptosis; Cancer; Target therapy; Tumor infiltrating lymphocytes

Indexed keywords

TUMOR MARKER;

ANIMAL; FEMALE; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; BIOMARKERS, TUMOR; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; OVARIAN NEOPLASMS;

EID: 84930147529     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.9.3635     Document Type: Short Survey

References (31)

1. Bachmayr-Heyda A, Aust S, Heinze G, et al (2013). Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium. BMC Cancer, 13, 422.
2. Bian J, Li B, Kou XJ, et al (2014). Clinical applicability of multitumor marker protein chips for diagnosing ovarian cancer. Asian Pac J Cancer Prev, 15, 8409-11.
3. Heintz AP, Odicino F, Maisonneuve P, et al (2006). Carcinoma of the ovary. FIGO 26th Annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet, 95, 161-92.
4. Clarke B, Tinker AV, Lee CH, et al (2009). Intraepithelial T cells and prognosis in ovarian carcinoma, novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol, 22, 393-402.
5. Clemente CG, Mihm MC Jr, Bufalino R, et al (1996). Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer, 77, 1303-10.
6. de Leeuw RJ, Kroeger DR, Kost SE, et al (2014). CD25 identifies a subset of CD4+FoxP3-TIL that are exhausted yet prognostically favorable in human ovarian cancer. Cancer Immunol Res, 2014.
7. Gasparri ML, Bellati F, Napoletano C, et al (2013). Interaction between Treg cells and angiogenesis, a dark double track. Int J Cancer, 132, 2469.
8. Giannakakis A, Karapetsas A, Dangaj D, et al (2014). Overexpression of SMARCE1 is associated with CD8+ T-cell infiltration in early stage ovarian cancer. Int J Biochem Cell Biol, 53, 389-98.
9. Guo CL, Yang HC, Yang XH, et al (2012). Associations between infiltrating lymphocyte subsets and hepatocellular carcinoma. Asian Pac J Cancer Prev, 13, 5909-13.
10. Hwang WT1, Adams SF, Tahirovic E, et al (2012). Prognostic significance of tumor-infiltrating T cells in ovarian cancer, a meta-analysis. Gynecol Oncol, 124, 192-8.
11. Jochems C1, Schlom J (2011). Tumor-infiltrating immune cells and prognosis, the potential link between conventional cancer therapy and immunity. Exp Biol Med, 236, 567-79.
12. Kroemer G1, Galluzzi L, Kepp O, et al (2013). Immunogenic cell death in cancer therapy. Annu Rev Immunol, 31, 51-72.
13. Leone Roberti Maggiore U, Bellati F, Ruscito I, Gasparri ML, et al (2013). Monoclonal antibodies therapies for ovarian cancer. Expert Opin Biol Ther, 13, 739-64.
14. Luo L, Dong LY, Yan QG. (2014) Research Progress in Applying Proteomics Technology to Explore Early Diagnosis Biomarkers of Breast Cancer, Lung Cancer and Ovarian Cancer. Asian Pac J Cancer Prev, 15, 8529-38.
15. Marchetti C, Imperiale L, Gasparri ML, et al (2012). Olaparib, PARP1 inhibitor in ovarian cancer. Expert Opin Investig Drugs, 21, 1575-84.
16. Mougiakakos D, Choudhury A, Lladser A, et al (2010). Regulatory T cells in cancer. Adv Cancer Res, 107, 57-117.
17. Napoletano C, Bellati F, Landi R, et al (2010). Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. J Cell Mol Med, 14, 2748-59.
18. Nielsen JS, Sahota RA, Milne K, et al (2012). CD20+ tumorinfiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res, 18, 3281-92.
19. Papadia A, Morotti M. (2013). Diaphragmatic surgery during cytoreduction for primary or recurrent epithelial ovarian cancer, a review of the literature. Arch Gynecol Obstet, 287, 733-41.
20. Paroli M, Bellati F, Videtta M, et al (2014). Discovery of chemotherapy-associated ovarian cancer antigens by interrogating memory T cells. Int J Cancer, 134, 1823-34.
21. Paulson KG, Carter JJ, Johnson LG, et al (2010).Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. Cancer Res, 70, 8388-97.
22. Raspollini MR, Castiglione F, Rossi Degl'innocenti D, et al (2005). Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol, 16, 590-6.
23. Salama M, Ormonde D, Quach T, et al (2010). Outcomes of endoscopic resection of large colorectal neoplasms, an Australian experience. J Gastroenterol Hepatol, 25, 84-9.
24. Santegoets SJ, Turksma AW, Suhoski MM, et al (2013). IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells. J Transl Med, 11, 37.
25. Sato E, Olson SH, Ahn J, et al (2005). Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A, 102, 18538-43.
26. Schreiber RD, Old LJ, Smyth MJ et al (2011). Cancer immunoediting, integrating immunity's roles in cancer suppression and promotion. Science, 331, 1565-70.
27. Tomsová M, Melichar B, Sedláková I, et al (2008). Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol, 108, 415-20.
28. Webb JR, Milne K, Watson P, et al (2014). Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res, 20, 434-44.
29. Yigit R, Massuger LF, Figdor CG, et al (2010). Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol, 117, 366-72.
30. Zhang L, Conejo-Garcia JR, Katsaros D, et al (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med, 348, 203-13.
31. Zitvogel L, Kepp O, Kroemer G. (2011) Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol, 8, 151-60.